PROTACs and Molecular Glues for Neurodegeneration

PROTACs and Molecular Glues for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PROTACs and Molecular Glues for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Physicochemical optimization</td>
<td>Lipophilicity, HBD/HBA optimization</td>
</tr>
<tr>
<td class="label">Prodrug approaches</td>
<td>Brain-targeted prodrugs</td>
</tr>
<tr>
<td class="label">Nanoparticle delivery</td>
<td>Lipid nanoparticles, [exosomes](/entities/exosomes)</td>
</tr>
<tr>
<td class="label">Focused ultrasound</td>
<td>BBB opening for enhanced delivery</td>
</tr>
<tr>
<td class="label">Receptor-mediated transcytosis</td>
<td>BBB shuttle molecules</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ARV-102</td>
<td>LRRK2</td>
</tr>
<tr>
<td class="label">Tau PROTAC</td>
<td>Tau</td>
</tr>
<tr>
<td class="label">α-Syn PROTAC</td>
<td>α-Synuclein</td>
</tr>
<tr>
<td class="label">mHTT PROTAC</td>
<td>Mutant [HTT](/proteins/huntingtin)</td>
</tr>
<tr>
<td class="label">Dual PROTAC T3</td>
<td>Tau + α-Syn</td>
</tr>
</table>

PROTACs and Molecular Glues for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PROTACs and Molecular Glues for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Physicochemical optimization</td>
<td>Lipophilicity, HBD/HBA optimization</td>
</tr>
<tr>
<td class="label">Prodrug approaches</td>
<td>Brain-targeted prodrugs</td>
</tr>
<tr>
<td class="label">Nanoparticle delivery</td>
<td>Lipid nanoparticles, [exosomes](/entities/exosomes)</td>
</tr>
<tr>
<td class="label">Focused ultrasound</td>
<td>BBB opening for enhanced delivery</td>
</tr>
<tr>
<td class="label">Receptor-mediated transcytosis</td>
<td>BBB shuttle molecules</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ARV-102</td>
<td>LRRK2</td>
</tr>
<tr>
<td class="label">Tau PROTAC</td>
<td>Tau</td>
</tr>
<tr>
<td class="label">α-Syn PROTAC</td>
<td>α-Synuclein</td>
</tr>
<tr>
<td class="label">mHTT PROTAC</td>
<td>Mutant [HTT](/proteins/huntingtin)</td>
</tr>
<tr>
<td class="label">Dual PROTAC T3</td>
<td>Tau + α-Syn</td>
</tr>
</table>

PROteolysis-TArgeting Chimeras (PROTACs) and molecular glue degraders represent a transformative therapeutic modality for neurodegenerative diseases. Unlike traditional small-molecule inhibitors that block protein function, these degraders recruit the cell's own [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) to selectively eliminate disease-causing proteins. This page provides a comprehensive analysis of this technology applied to [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and related neurodegenerative disorders.

Mechanism of Action

PROTAC Heterobifunctional Degraders

PROTACs are chimeric molecules consisting of three critical components:

Molecular Glue Degraders

Molecular glues are monovalent compounds that stabilize protein-protein interactions between a target protein and an E3 ligase, inducing degradation without the need for bifunctional design[@klein2024]. They offer:

• Smaller molecular weight (typically 300-500 Da vs 700-1000 Da for PROTACs)
• Better drug-like properties including CNS penetration
• Novel binding modes not accessible to traditional PROTACs

CNS Targets for Neurodegeneration

Tau Protein (Alzheimer's Disease and Tauopathies)

[Tau](/proteins/tau) pathology is the strongest correlate of cognitive decline in [Alzheimer's disease](/diseases/alzheimers-disease). PROTACs offer unique advantages over other [tau](/proteins/tau)-targeting approaches:

• Intracellular access: Majority of pathological tau is intracellular, inaccessible to antibodies
• Catalytic clearance: Single PROTAC molecule can degrade multiple tau copies
• Conformer selectivity: Can be engineered to preferentially bind pathological phosphorylated forms

Dual PROTACs: Compounds like T3 simultaneously degrade both [alpha-synuclein](/proteins/alpha-synuclein) and tau, addressing copathology common in neurodegeneration[@gao2024].

alpha-Synuclein (Parkinson's Disease, DLB, MSA)

[alpha-synuclein](/proteins/alpha-synuclein) aggregation into [Lewy bodies](/mechanisms/lewy-body-formation) characterizes [Parkinson's disease](/diseases/parkinsons-disease), [Lewy body dementia](/diseases/lewy-body-dementia), and [multiple system atrophy](/diseases/multiple-system-atrophy).

PROTACs targeting alpha-synuclein have demonstrated:

• DC50 values in low nanomolar range
• Degradation approaching 80% for lead molecules
• Selective clearance of oligomeric and fibrillar forms[@gao2024]

TDP-43 (ALS, FTLD)

[TDP-43](/proteins/tdp-43) proteinopathy characterizes approximately 97% of [ALS](/diseases/amyotrophic-lateral-sclerosis) and ~50% of [FTD](/diseases/frontotemporal-dementia) cases. PROTACs targeting mislocalized or aggregated [TDP-43](/mechanisms/tdp-43-proteinopathy) are in early preclinical development.

Molecular glue approaches for TDP-43 include:

• Inducers of nuclear import: Small molecules promoting TDP-43 nuclear localization
• Aggregation inhibitors: Compounds preventing stress granule sequestration

LRRK2 (Parkinson's Disease)

[LRRK2](/proteins/lrrk2-protein) mutations are the most common genetic cause of familial [Parkinson's disease](/diseases/parkinsons-disease). ARV-102 is the most clinically advanced CNS PROTAC:

• Orally bioavailable, brain-penetrant
• Degraded LRRK2 by nearly 90% in non-human primate brain
• Demonstrated CSF drug levels confirming [BBB](/entities/blood-brain-barrier) penetration
• Phase 1b trial in PSP planned for 2026[@arvinas2025]

Mutant Huntingtin (Huntington's Disease)

PROTACs can selectively degrade mutant [huntingtin](/proteins/huntingtin) while sparing wild-type protein — a key advantage over [antisense oligonucleotides](/therapeutics/antisense-oligonucleotide-therapies) like tominersen that reduce both forms.

Delivery Challenges for CNS

Blood-Brain Barrier Penetration

PROTACs' larger molecular weight (700-1000 Da) poses significant BBB challenges. Strategies to improve penetration include:

Target Selectivity

Achieving selective degradation of pathological protein species while sparing physiological forms is critical:

• Conformation-selective warheads: Bind preferentially to aggregated/modified forms
• Tissue-specific E3 ligases: Limit degradation to affected brain regions
• Context-dependent degradation: Only in cells with high target levels

Hook Effect

At high concentrations, PROTACs can saturate both target and E3 ligase separately, preventing ternary complex formation. This inverted U-shaped dose-response requires careful clinical dosing optimization.

Clinical Development Landscape

Related Technologies

Lysosome-Targeting Chimeras (LYTACs)

LYTACs redirect extracellular and membrane proteins to lysosomes via mannose-6-phosphate receptors. Particularly useful for:

• Extracellular [amyloid-beta](/proteins/amyloid-beta)
• Secreted alpha-synuclein
• Membrane protein targets

Autophagy-Targeting Chimeras (AUTACs)

AUTACs leverage [autophagy](/entities/autophagy) for degradation, essential for large protein aggregates that exceed proteasome capacity. Particularly relevant for:

• Large fibrils and inclusions
• Mitochondrial clearance
• Aggresome targeting

Antibody-Based Degraders (AbTACs)

Bispecific antibodies recruiting membrane E3 ligases (RNF43) for degradation of cell-surface and extracellular targets.

Future Directions

The field is rapidly evolving toward:

See Also

• [Targeted Protein Degradation (PROTACs)](/therapeutics/targeted-protein-degradation-protacs)
• [LRRK2 Inhibitors](/therapeutics/lrrk2-inhibitors)
• [Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics)
• [alpha-Synuclein Immunotherapy](/therapeutics/alpha-synuclein-immunotherapy)
• [Autophagy-Enhancing Therapies](/therapeutics/autophagy-enhancing-therapies)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;